Please enjoy my interview with Absci CEO Sean McClain “We're on track to put the first de novo designed antibody with generative AI in the clinic in early 2025.” Absci, a biotech startup using “generative AI” to create novel therapeutics, is hopefully just one year away from

→ View original post on X — @tiernanraytech,